AAPP had a busy year advocating on behalf of the membership with Congress and the Administration amidst a rapidly changing federal landscape. Throughout the year, AAPP worked to advance the policy priorities outlined in the 2025 Health Policy Agenda. As the new year begins, we look back on the advocacy activities AAPP was engaged in last year with the expectation that 2026 will be full of activity once again.
No summary available
Our analyses characterized the landscape of shared and divergent genetic influences of common variants on 14 psychiatric disorders.
On March 19 from 4:00-5:30 PM ET NAMI will host this presentation to provide an overview of catatonia and discuss the various potential causes of catatonia, as well as the many different ways in which the syndrome may manifest.
The Stigma Unraveled/Addiction Unmasked interprofessional workshop prompted meaningful and statistically significant changes in participant beliefs, attitudes, behaviors, and knowledge.
Policy interventions and pharmacist advocacy are needed to alleviate challenges.
CPPs provided MOUD care that was safe and effective and outcomes were comparable to physicians and nurse practitioners.
The pharmacist-led intervention more than doubled the pharmacologic treatment rate for AUD in primary care.
A dedicated Pain Management CPS with a focus on addiction medicine provides significant clinical and financial value in the inpatient setting.
NAMI has relaunched its #Vote4MentalHealth campaign for the 2026 elections. This nonpartisan campaign is part of NAMI’s long-standing efforts to help people across the country understand that voting and mental health are closely intertwined and find the resources and information they need to cast their ballot. NAMI urges voters to take the pledge to #Vote4MentalHealth, which is a commitment to do one thing: understand how your vote impacts mental health.
No summary available
The new platform provides for analyzing adverse event reports.
Data suggest that prevalence of cigarette smoking among U.S. adults declined from 10.8% of the population in 2023 to 9.9% in 2024.
AAPP is a member of a pharmacy‑based vaccine access work group composed of national pharmacy organizations. The work group is conducting a survey to gather insights into vaccination practices since June 2025. Feedback will support pharmacy organizations in their advocacy and education efforts. If applicable to your practice, please complete the survey, available through March 31, 2026.
These findings provide a framework for the long-term evaluation of intervention programs and guiding health care resource allocation to reduce adolescent alcohol consumption.
Removal of transmucosal buprenorphine PA requirements for Kentucky Medicaid enrollees was associated with a significant immediate increase in buprenorphine dispensing for OUD treatment.
Emerging evidence suggests novel OAT induction strategies for fentanyl-related OUD are feasible and show a consistent direction toward positive clinical and safety outcomes.
This cohort study found that OPC opening was not associated with significant changes in local economic activity.
This study's findings suggest an association between fluoroquinolones and increased risk of panic attacks.
These resources provide practical toolkits and clinical guidance.
No summary available
No summary available
Use of GLP-1 receptor agonists was consistently associated with reduced risks of developing various incident SUDs, suggesting a broad preventive effect across multiple substance types.
AAPP President Jolene Bostwick talks about the future and our new strategic plan.
This blog series by the Resident and New Practitioner Committee is targeted to psychiatric pharmacists seeking their first or a new position. This blog explores opportunities in the pharmaceutical industry.